Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Incyte Corporation Call Center (US)
- Phone Number: 1.855.463.3463
- Email: medinfo@incyte.com
Study Contact Backup
- Name: Incyte Corporation Call Center (ex-US)
- Phone Number: +800 00027423
- Email: eumedinfo@incyte.com
Study Locations
-
-
New South Wales
-
Concord, New South Wales, Australia, 02139
- Recruiting
- Concord General Repatriation Hospital
-
St Leonards, New South Wales, Australia, 02065
- Recruiting
- Royal North Shore Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australia, 04066
- Recruiting
- Icon Cancer Centre
-
-
Victoria
-
East Melbourne, Victoria, Australia, 03002
- Recruiting
- Epworth Health Care
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 06009
- Recruiting
- Linear Clinical Research
-
-
-
-
-
Liège, Belgium, 04000
- Not yet recruiting
- Centre Hospitalier Universitaire (Chu) de Liege
-
Roeselare, Belgium, 08800
- Not yet recruiting
- AZ DELTA
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Not yet recruiting
- McGill University Jewish General Hospital
-
-
-
-
-
Bordeaux, France, 33076
- Recruiting
- Francois-Xavier
-
Paris, France, 75010
- Recruiting
- Hospital Saint Louis
-
Villejuif, France, 94805
- Recruiting
- Institut Gustave Roussy
-
-
-
-
-
Aachen, Germany, D-52074
- Recruiting
- University Medical Center Rwth Aachen
-
Berlin, Germany, 10117
- Recruiting
- Charite Universitaetsmedizin Berlin - Campus Charite Mitte
-
Freiburg im Breisgau, Germany, 79106
- Recruiting
- Universitatklinikum Freiburg
-
Halle, Germany, 06120
- Recruiting
- Universitatsklinikum Halle (Saale)
-
Mainz, Germany, 55131
- Not yet recruiting
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
-
-
-
-
Bologna, Italy, 40138
- Not yet recruiting
- Aou Policlinico S. Orsola-Malpighi
-
Milan, Italy, 20122
- Not yet recruiting
- Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
-
Roma, Italy, 00168
- Not yet recruiting
- A. Gemelli University Hospital, Catholic University of the Sacred Heart
-
Udine, Italy, 33100
- Not yet recruiting
- Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
-
-
-
-
-
Kashiwa Chiba, Japan, 277-0882
- Not yet recruiting
- National Cancer Center Hospital East
-
Toon, Ehime, Japan, 791-0204
- Not yet recruiting
- Ehime University Hospital
-
-
-
-
-
Jongno-gu, Seoul, South Korea, 03080
- Not yet recruiting
- Seoul National University Hospital
-
Seocho-gu, Seoul, South Korea, 06591
- Not yet recruiting
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Badalona, Spain, 08916
- Not yet recruiting
- Hospital Universitari Germans Trias I Pujol
-
Las Palmas de Gran Canaria, Spain, 35010
- Not yet recruiting
- Hospital Universitario de Gran Canaria Dr. Negrin
-
Madrid, Spain, 28041
- Not yet recruiting
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Not yet recruiting
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
Nottingham, United Kingdom, NG5 1PB
- Not yet recruiting
- Nottingham University Hospitals
-
Oxford, United Kingdom, OX3 7LE
- Recruiting
- University of Oxford
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Not yet recruiting
- University of Alabama At Birmingham
-
-
California
-
Irvine, California, United States, 92618
- Recruiting
- City of Hope-Lennar Foundation Cancer Center
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- UCLA Medical Hematology & Oncology
-
Los Angeles, California, United States, 90033
- Not yet recruiting
- Usc Norris Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Not yet recruiting
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136
- Not yet recruiting
- University of Miami
-
Tampa, Florida, United States, 33612
- Not yet recruiting
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute of Emory University
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Not yet recruiting
- John Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, United States, 63108
- Not yet recruiting
- Washington University School of Medicine
-
-
New York
-
New York, New York, United States, 10065
- Not yet recruiting
- Weill Cornell Medicine
-
New York, New York, United States, 10029
- Not yet recruiting
- Mount Sinai School of Medicine
-
New York, New York, United States, 10021
- Not yet recruiting
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, United States, 28204
- Not yet recruiting
- Levine Cancer Institute
-
Durham, North Carolina, United States, 27705
- Not yet recruiting
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Not yet recruiting
- Cleveland Clinic
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tristar Bmt/Tcto
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- University of Texas M. D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Not yet recruiting
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Not yet recruiting
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1a: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. |
|
Experimental: Part 1b: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
|
Experimental: Part 2a: Dose Expansion
INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1 |
INCA036978 will be administered at protocol defined dose. |
|
Experimental: Part 2b: Dose Expansion
INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Time Frame: Up to 28 days
|
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. |
Up to 28 days
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to approximately 2 years
|
Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first. |
Up to approximately 2 years
|
|
Number of participants with TEAEs leading to dose modification or discontinuation
Time Frame: Up to approximately 2 years
|
Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation. |
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics Parameter: Cmax of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as maximum observed plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Tmax of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the time to reach the maximum plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the maximum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the minimum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the area under the concentration-time curve from 0 to infinity of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: CL/F of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the apparent clearance of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Vz/F of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the apparent volume of distribution of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: t1/2 of INCA036978
Time Frame: Up to approximately 2 years
|
Defined as the apparent terminal phase disposition half-life of INCA036978. |
Up to approximately 2 years
|
|
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Time Frame: Week 12 and Week 24
|
Defined as percentage of participants with a protocol defined spleen volume reduction. |
Week 12 and Week 24
|
|
For participants with MF and anemia: Anemia Response as defined in the protocol
Time Frame: Up to approximately 2 years
|
For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol. |
Up to approximately 2 years
|
|
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Time Frame: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
|
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Time Frame: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Incyte Medical Monitor, Incyte Corporation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Hematologic Diseases
- Blood Coagulation Disorders
- Bone Marrow Diseases
- Hemorrhagic Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Hemic and Lymphatic Diseases
- Thrombocytosis
- Myeloproliferative Disorders
- Thrombocythemia, Essential
- Polycythemia Vera
- Primary Myelofibrosis
Other Study ID Numbers
Other Study ID Numbers
- INCA036978-101
- 2026-525217-31-00 (Registry Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.